Language

Chinese English

Conference Information

Home page

NewCo Reaches Monetization Moment

Mar 31,2026

Hengrui Medicine-Backed NewCo Launches IPO

Behind Eli Lilly’s Massive $2.8 Billion Investment: Chinese Innovative Pharmaceutical Companies Take the Stage

Mar 30,2026

An Irreversible Wave

A “veteran of Zhangjiang’s Pharmaceutical Valley” and his firsthand account of two decades of innovative drug development in China

Mar 29,2026

On Perseverance, Transformation, and Expectation

CPIC 2026 | Junlian Capital & Rxilient Special Session: Global Expansion of Pharmaceutical Companies and Collaboration in Emerging Markets

Mar 29,2026

Legend Capital, Rxilient, and TONACEA are jointly hosting a special session themed "Global Development of Pharmaceutical Enterprises and Emerging Market Collaboration." The session will focus on the latest policies, market opportunities and challenges, product and industry go-to-market strategies, and localization practices in Southeast Asia, the Middle East and North Africa, and Latin America.

AI-Driven Drug Discovery Ushers in “China’s Moment”

Mar 28,2026

Standing in the spotlight, waiting

Innovation is shifting eastward—where does regulation stand?

Mar 27,2026

The United States and China in the New World Order

Multinational Pharmaceutical Companies Are “Increasing Their Positions” in China

Mar 25,2026

A Vote of Confidence Worth Over Hundreds of Billions

8 Billion in M&A Within Two Days: China’s Innovative Drugs Are Becoming Global “Hard Currency”

Mar 25,2026

Making Its Way to the Center of the Global Stage